CD8A and neoplasm: Healthy C57BL/6 mice that were vaccinated with the MC-38 fusion cell membrane-coated nanoparticles for two consecutive weeks before MC-38 tumour cell inoculation revealed to have benefitted from significant anti-tumour protection with enhanced infiltration of CD4+ and CD8+ T cells in the tumour.